Literature DB >> 6130081

Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment.

R S Hausner.   

Abstract

Although Parkinson's disease can occur in individuals with psychosis, a patient on antipsychotic medication who develops parkinsonian signs may more readily be diagnosed as and treated for neuroleptic-induced parkinsonism. There are several clinically significant criteria that may aid in proper diagnosis, including clinical course, time and age of onset, nature of tremor, unilaterality of signs, and response to anticholinergic medication. Appropriate diagnosis is essential, as treatment approaches differ for the two disorders. Four case studies are presented to highlight the diagnostic criteria and therapeutic ramifications.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6130081

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


  8 in total

1.  Aripiprazole-induced parkinsonism in a child: a case report.

Authors:  Harshad Patel; Ankit Patel; Saira Mushtaq; Fasiha Haq; Shakeel Raza
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.

Authors:  R J Hardie; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

Review 3.  Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations.

Authors:  M R Caligiuri; D V Jeste; J P Lacro
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

4.  Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs.

Authors:  V Bocola; G Fabbrini; A Sollecito; C Paladini; N Martucci
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

5.  Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.

Authors:  T M Hyde; M F Egan; L L Wing; R J Wyatt; D R Weinberger; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

6.  Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.

Authors:  Michele Tinazzi; Angelo Antonini; Tommaso Bovi; Isabella Pasquin; Maria Steinmayr; Giuseppe Moretto; Antonio Fiaschi; Sarah Ottaviani
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

Review 7.  Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.

Authors:  Lior Greenbaum; Bernard Lerer
Journal:  Front Neurol       Date:  2015-02-20       Impact factor: 4.003

8.  Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study.

Authors:  Ditte Rudå; Gudmundur Einarsson; Anne Sofie Schott Andersen; Jannik Boll Matthiassen; Christoph U Correll; Kristian Winge; Line K H Clemmensen; Rasmus R Paulsen; Anne Katrine Pagsberg; Anders Fink-Jensen
Journal:  Front Neurol       Date:  2021-01-06       Impact factor: 4.003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.